Oct. 25 Company Quick Takes: Astellas gets European approval for AML therapy; plus Acorda, Amgen, Illumina-PacBio and Qpex-Brii

Astellas’ Xospata wins AML approval in Europe
The European Commission has approved Xospata gilteritinib from Astellas Pharma Inc. (Tokyo:4503) as a monotherapy for relapsed or refractory acute myelogenous leukemia with an FLT3 Mutation. The oral small molecule AXL and FLT3 inhibitor is already approved in the U.S. and Japan for the indication.

Acorda to cut 25% of staff by 1Q20
Acorda Therapeutics Inc. (NASDAQ:ACOR) said it will reduce headcount by 25%, which the neurology company estimates will save about $21 million. Acorda had about $253 million in cash as of Sept. 30...